Antimicrobial Photodynamic Therapy for Hospital-Acquired Infections
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to prevent infections in ICU patients using antimicrobial photodynamic therapy (aPDT). This involves applying a special light and substance to the nose to kill germs. The study will compare patients receiving this treatment with those who do not, to determine if it reduces infections such as pneumonia and bloodstream infections. Patients who have been in the ICU for more than two days and do not have nasal injuries or certain allergies might be suitable candidates. As an unphased trial, this study provides an opportunity for patients to contribute to innovative research that could enhance infection prevention in critical care settings.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this protocol is safe for preventing hospital-acquired infections?
Research has shown that antimicrobial photodynamic therapy (aPDT) could effectively kill various bacteria, including those responsible for hospital infections. Studies have found that aPDT can reduce harmful bacteria on hospital surfaces, potentially preventing infections like pneumonia or bloodstream infections.
Regarding safety, aPDT is generally well-tolerated. Previous studies have not identified any major safety issues, supported by its use in treating other conditions, such as dental biofilms. While further research is needed to confirm these findings, current evidence suggests that aPDT is a safe option for reducing bacterial infections.12345Why are researchers excited about this trial?
Unlike the standard of care for hospital-acquired infections, which typically involves antibiotics, antimicrobial photodynamic therapy (aPDT) uses light-sensitive compounds and a specific wavelength of light to destroy harmful bacteria. This method is unique because it targets bacteria directly, minimizing the risk of antibiotic resistance, a major concern with current treatments. Moreover, aPDT can be precisely applied to infected areas, potentially reducing side effects associated with systemic antibiotic use. Researchers are excited about this approach because it offers a novel, potentially more effective way to manage infections without contributing to the growing issue of antibiotic resistance.
What evidence suggests that antimicrobial photodynamic therapy is effective for preventing hospital-acquired infections?
Research has shown that antimicrobial photodynamic therapy (aPDT) can significantly reduce bacteria, including resistant strains like MRSA. In studies, aPDT consistently reduced these bacteria by 99.9%. It uses light to activate a substance that kills harmful germs. In this trial, participants in the intervention arm will receive aPDT as part of nasal decolonization procedures. When combined with antibiotics, aPDT can enhance treatment effectiveness and help prevent antibiotic resistance. It has proven effective and generally well-tolerated in various situations. However, infections can sometimes return, so ongoing treatment might be necessary.12567
Who Is on the Research Team?
Steven Reynolds
Principal Investigator
Fraser Health Authority
Are You a Good Fit for This Trial?
This trial is for patients in the critical care unit at Royal Columbian Hospital who may be at risk of hospital-acquired pneumonia or bloodstream infections. The study aims to include those who could benefit from nasal decolonization to prevent these infections.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Control Period
The first two months will constitute the control period before the aPDT intervention is introduced. No nasal decolonization procedures will take place at this time.
Intervention Period
Nasal decolonization procedures will be administered every other day. Nasal swabs will be collected every four days to assess microbiology.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a nasal swab collected 4-days post-ICU discharge if still hospitalized.
What Are the Treatments Tested in This Trial?
Interventions
- Antimicrobial photodynamic therapy (aPDT)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fraser Health
Lead Sponsor
Royal Columbian Hospital Foundation
Collaborator
Ondine Biomedical Inc.
Industry Sponsor
Royal Columbian Hospital Foundation
Collaborator